Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBT (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed EBT for 7 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 376.71% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 million through Dec 2025, down 19.7% year-over-year, with the annual reading at -$4.6 million for FY2025, 19.7% down from the prior year.
  • EBT hit $1.4 million in Q4 2025 for Eton Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.1 million in Q1 2021 to a low of -$6.1 million in Q3 2021.
  • Historically, EBT has averaged -$1.0 million across 5 years, with a median of -$1.5 million in 2022.
  • Biggest five-year swings in EBT: soared 392.62% in 2023 and later crashed 490.22% in 2025.
  • Year by year, EBT stood at $1.0 million in 2021, then dropped by 12.22% to $912000.0 in 2022, then tumbled by 320.29% to -$2.0 million in 2023, then soared by 74.56% to -$511000.0 in 2024, then soared by 376.71% to $1.4 million in 2025.
  • Business Quant data shows EBT for ETON at $1.4 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.5 million in Q2 2025.